Overview:
Founder Bio — Dr Daniel DeBrouse
Inventor, Materials Scientist, Molecular Microbiologist, Drug Delivery Expert, and Founder of Sacralin™ Biopolymers
Author of “The Rise of Structural Polysaccharides”
Dr Daniel DeBrouse is a materials scientist and pioneering researcher in the emerging field of structural polysaccharide–based bioplastics. He is the original author of The Rise of Structural Polysaccharides, one of the early works describing how agar, alginate, glycerin, and related natural polymers can be engineered into thermoformable, mechanically tunable, and fully biodegradable alternatives to petroleum-based plastics.
With more than two decades of hands-on experimentation and process development, Dr DeBrouse has developed a deep understanding of how polysaccharides behave under thermal, mechanical, and moisture-dependent conditions. His work bridges polymer science and practical manufacturing, focusing on:
Drop-in material compatibility with existing plastic extrusion, pelletizing, injection molding, and thermoforming lines
Biodegradation kinetics and structural breakdown pathways in soil, marine, and compost environments
Mechanical tuning through glycerin ratios, crosslinking behavior, and water-binding characteristics
Thermal stabilization and processing-window optimization for industrial throughput
Sustainability engineering, including microplastic elimination and circular materials design
Dr DeBrouse is the inventor of Sacralin™, a next-generation biodegradable pellet made from alginates, agar, and glycerin — engineered to run on conventional plastic equipment with no retooling. His scientific insights into polysaccharide systems form the foundation of Sacralin’s performance, reliability, and industrial scalability.
He has collaborated with operators, engineers, and sustainability leaders across multiple industries, helping them integrate renewable biomaterials into existing manufacturing processes without sacrificing output, consistency, or product function.
Today, Dr DeBrouse leads Sacralin Biopolymers in advancing structural polysaccharides as a global platform technology for sustainable materials, supporting applications across food packaging, consumer goods, logistics, automotive components, and more. His mission is to accelerate the transition away from fossil-based plastics by making biodegradable solutions simple, scalable, and immediately adoptable.
Dr. Daniel DeBrouse is also a scientist specializing in molecular microbiology and biotechnology. He is known for his work in biomimicry, drug delivery technologies, and innovative biodegradable materials.
He founded MicroTech in 1998, a private lab focusing on rapid microbiological and chemical analyses of food, including pioneering RNA probe–based assays to detect pathogens like Listeria in just 18 hours.
Around 2008, he was appointed as a Professor of Research in the Chemistry Department at Syracuse University, recognizing his contributions to rapid detection technologies and molecular science.
Key Innovations & Contributions:
Oral Insulin and Drug Delivery:
In 2012, he gained international attention by developing what may be the first clinically viable oral insulin formulation. His Serum-Specific Nano-encapsulation (SSNe) delivery system protects therapeutic agents through the digestive tract, enabling efficient absorption into the bloodstream. Reported bioavailability ranged between 73% and 98%, a significant improvement over conventional methods.
Biodegradable Building Materials:
He has also developed BioCrete, a formulation using marine polymers as an eco-friendly alternative to concrete, featured on the cover of Architecture Magazine in 2013.
Biomimicry in Fermentation:
DeBrouse contributed to the biotech industry by pioneering “Biosymbiotic Fermentation,” where communities of microbes cooperatively produce, isolate, and purify bioactive substances—advancing biomimicry in industrial processes.
Virology and Antiviral Research:
In molecular virology, he conducted research on recombinant strategies against HIV-1, hepatitis C virus (HCV), recombinant vaccines, antivirals, and proposed novel in vivo models such as chimeric mice for HCV studies.
Professional Roles & Leadership:
He was the Founder, CEO and Chief Scientific Officer of Tamarisk Technologies, LLC and Tamarisk Technologies Group, companies he founded in 2009 to further his multidisciplinary research across drug delivery, sustainable materials, automotive technologies, alternative energy, and biotech.
He was also Chief Scientific Officer of Advanced Molar Innovations, working on 100% biodegradable building materials. Plastics News
Dr DeBrouse holds a Ph.D. in Molecular Microbiology from CSU.
Summary Snapshot:
Food microbiology
Rapid Listeria detection assays at MicroTech
Drug delivery
SSNe system enabling oral insulin with high bioavailability
Biomimicry & fermentation
Biosymbiotic Fermentation methods for biotech applications
Sustainable materials
BioCrete—marine polymer–based biodegradable alternative to concrete
Molecular virology
Research on HIV-1, HCV, vaccines, antivirals, and in vivo models
Leadership & innovation
CEO/CSO roles at Tamarisk Technologies, involvement with Advanced Molar Innovations